REGN5458 for relapsed or refractory multiple myeloma


featured image

REGN5458 is in clinical development for the treatment of adults with multiple myeloma (MM) whose disease has returned following treatment.

Interventions: REGN5458
Indications: Multiple myeloma (MM)
Year: 2022

REGN5458 is in clinical development for the treatment of adults with multiple myeloma (MM) whose disease has returned following treatment. MM is a form of cancer that occurs in immune cells found in bone marrow. The disease occurs due to uncontrolled duplication of these immune cells, known as plasma cells. Symptoms of MM can include broken bones or bone pain, fatigue, persistent infections, nausea and spinal cord compression. Despite many different therapeutic options being available to people with MM, the disease often returns following treatment.